Filana Therapeutics (FLNA): CEO bought ~$107K
Richard Barry, CEO at Filana Therapeutics, bought ~$107K of Filana Therapeutics shares.
- ~$107K
- Approx. value · 47K sh @ $2.29
- 708K
- Holds after · shares reported
- Traded
- Sep 19, 2025
- Filed
- Sep 22, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Sep 18, 2025Insider · 1 personInsiders: 2 purchases (~$426K)
- Sep 19, 2025 · this disclosureInsiderCEO purchased ~$107K of FLNA shares in the open market
What came next
- Sep 19, 2025InsiderCEO purchased ~$900 of FLNA shares in the open market
- Sep 22, 2025InsiderCEO purchased ~$16K of FLNA shares in the open market
- Oct 21, 2025Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors
- Oct 21, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member
- Nov 12, 2025Company filing · Form 8-K · ResultsReported its results
- Nov 19, 2025InsiderCEO purchased ~$202K of FLNA shares in the open market
- Nov 20, 2025InsiderCEO purchased ~$414K of FLNA shares in the open market
- Nov 24, 2025Insider · Their first buy on recordDirector purchased ~$25K of FLNA shares in the open market
- Dec 12, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 12, 2025, the Board of Directors (the “Board”) of Cassava Sciences, Inc. (the “Company”) approved cash bonus awards for calendar 2025 for the Company’s named executive officers in recognition of their contributions to the Company as follows: Name Title Bonus Amount Richard J. Barry President & Chief Executive Officer $ 355,000 Eric J. Schoen Chief Financial Officer $ 215,000 For 2025, the Board…”
- Dec 19, 2025Company filing · Form 8-K · Material agreementSigned an important agreement
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Filana Therapeutics
For Filana Therapeutics, OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its FLNA page.
Other recent filings by Richard Barry, President & CEO
- SEC Form 4 at Filana Therapeutics (FLNA)Oct 1, 2026
- SEC Form 4 at Filana Therapeutics (FLNA)Oct 1, 2026
- SEC Form 4 at Filana Therapeutics (FLNA)Sep 30, 2026
- SEC Form 4 at Filana Therapeutics (FLNA)Nov 24, 2025
- SEC Form 4 at Filana Therapeutics (FLNA)Nov 20, 2025
The full history of Richard Barry, President & CEO is on the profile page.
How this filing works
Explore the data
Common questions
Which Filana Therapeutics (FLNA) insider traded, and how much?
Richard Barry, CEO at Filana Therapeutics, bought ~$107K of Filana Therapeutics shares. 47K shares at $2.29, open market.
When did it happen, and when was it made public?
Traded: Sep 19, 2025. Filed: Sep 22, 2025. That is 3 days between the two dates.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Filana Therapeutics recently?
For Filana Therapeutics, OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the FLNA page.
Does this mean FLNA stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Filana Therapeutics
- SEC Form 4Oct 1, 2026
- SEC Form 4Oct 1, 2026
- SEC Form 4Sep 30, 2026
- SEC Form 4Nov 25, 2025
- SEC Form 4Nov 24, 2025
- SEC Form 4Nov 20, 2025
Everything OQRO holds on this company is on its FLNA page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data